We provide you with 20 years of free, institutional-grade data for YMAB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of YMAB. Explore the full financial landscape of YMAB stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-08 | 1722964 | YMAB | 10-Q | Url |
| 2025-05-13 | 1722964 | YMAB | 10-Q | Url |
| 2025-03-04 | 1722964 | YMAB | 10-K | Url |
| 2024-11-08 | 1722964 | YMAB | 10-Q | Url |
| 2024-08-12 | 1722964 | YMAB | 10-Q | Url |
| 2024-05-07 | 1722964 | YMAB | 10-Q | Url |
| 2024-02-29 | 1722964 | YMAB | 10-K | Url |
| 2023-11-13 | 1722964 | YMAB | 10-Q | Url |
| 2023-08-10 | 1722964 | YMAB | 10-Q | Url |
| 2023-05-08 | 1722964 | YMAB | 10-Q | Url |
| 2023-03-30 | 1722964 | YMAB | 10-K | Url |
| 2022-11-07 | 1722964 | YMAB | 10-Q | Url |
| 2022-08-08 | 1722964 | YMAB | 10-Q | Url |
| 2022-05-09 | 1722964 | YMAB | 10-Q | Url |
| 2022-03-01 | 1722964 | YMAB | 10-K | Url |
| 2021-11-04 | 1722964 | YMAB | 10-Q | Url |
| 2021-08-09 | 1722964 | YMAB | 10-Q | Url |
| 2021-05-06 | 1722964 | YMAB | 10-Q | Url |
| 2021-03-01 | 1722964 | YMAB | 10-K | Url |
| 2020-11-05 | 1722964 | YMAB | 10-Q | Url |
| 2020-08-06 | 1722964 | YMAB | 10-Q | Url |
| 2020-05-07 | 1722964 | YMAB | 10-Q | Url |
| 2020-03-12 | 1722964 | YMAB | 10-K | Url |
| 2019-11-13 | 1722964 | YMAB | 10-Q | Url |
| 2019-08-14 | 1722964 | YMAB | 10-Q | Url |
| 2019-05-10 | 1722964 | YMAB | 10-Q | Url |
| 2019-03-22 | 1722964 | YMAB | 10-K | Url |
| 2018-11-13 | 1722964 | YMAB | 10-Q | Url |
| 2018-08-24 | 1722964 | YMAB | S-1 | Url |
Y-mAbs Therapeutics, Inc(NASDAQ:YMAB) 
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophag...
Website: http://www.ymabs.com
Founded: 2015
Full Time Employees: 65
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about YMAB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.